Shares of Prothena Corporation PRTA plummeted 53.5% year to date compared with the industry’s decline of 0.6%. The recent ...

The move helps in expediting the enrolment process for central nervous system, vaccine, as well as specialty trials.

A panelist discusses how the POD1UM-303 randomized phase 3 trial demonstrated that adding retifanlimab (a PD-1 inhibitor) to ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...